AIT Webinar Series 2020:
On behalf of the AIT, I hope that you, your family and also your colleagues are well and continuing to stay safe during these unusual times.
The AIT Committee have been working hard on providing a series of webinar talks to be held in place of the annual conference during October 2020. All webinars will be a 30-minute presentation with a 10-minute Q&A session (questions sent in during the presentation to be answered at the end).
Provisional dates are as follows (TBC)/time is 1pm UK time:
Tuesday 13th October 2020: COVID-19 talk
Thursday 15th October 2020: Early De-risking Approaches for Identification of Anti-Fibrotics for Idiopathic Pulmonary Fibrosis Treatment – 3 assays discussed
Tuesday 20th October 2020: Phase I Clinical Trials
Thursday 22nd October 2020: Presentation from US and UK regulators: Calculation of and the acceptable safety margins from preclinical to clinical studies.
As soon as the webinar titles/dates are all confirmed, members of the AIT will be informed and the webinar details will be posted on the AIT Group LinkedIn page and on the AIT website. Places to attend each webinar will be limited and you will be asked to register for each talk you want to attend. Early registration is highly recommended.
Registration details will be posted soon.....
AIT CONFERENCE - Notification of delay 2020
After some very difficult discussions and careful consideration of the expanding coronavirus outbreak, and to ensure the safety and well-being of our organisers, participants and speakers, the AIT has reluctantly taken the decision to postpone the AIT conference for 1 year (Tuesday 19th to Thursday 21st October 2021 in Gothenburg, Sweden).
We will be organising some online training courses during October 2020 in place of the F2F conference (topics to be confirmed). Notifications will be sent out as soon as dates and topics are confirmed.
The AIT committee hope you all stay safe and well during the current pandemic.
Presenters and Exhibitors please contact the AIT for conference details at firstname.lastname@example.org.